HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
GlobeNewswire
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo —— Presentations at EHA..
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo —— Presentations at EHA..
SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges FAT Brands Inc. *(NASDAQ: FAT, FATBB, FATBP, FATBW)* investors..
LOS ANGELES, June 12, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting..